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BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells,
which express high levels of cannabinoid receptor types 1 and 2 (CB1 and CB2). In this study, we investigated the role of CB2
receptor in the anti-proliferative action of cannabinoids and the signal transduction triggered by receptor ligation.
METHODS: The human prostate cancer cell lines, namely PC-3, DU-145 and LNCaP, were used for this study. Cell proliferation was
measured using MTT proliferation assay, [
3H]-thymidine incorporation assay and cell-cycle study by flow cytometry. Ceramide
quantification was performed using the DAG kinase method. The CB2 receptor was silenced with specific small interfering RNA, and
was blocked pharmacologically with SR 144528. In vivo studies were conducted by the induction of prostate xenograft tumours in
nude mice.
RESULTS: We found that the anandamide analogue, R(þ)-Methanandamide (MET), as well as JWH-015, a synthetic CB2 agonist,
exerted anti-proliferative effects in PC-3 cells. R(þ)-Methanandamide- and JWH-015-induced cell death was rescued by treatment
with the CB2 receptor antagonist, SR 144528. Downregulation of CB2 expression reversed the effects of JWH-015, confirming the
involvement of CB2 in the pro-apoptotic effect of cannabinoids. Further analysing the mechanism of JWH-015-induced cell growth
inhibition, we found that JWH-015 triggered a de novo synthesis of ceramide, which was involved in cannabinoid-induced cell death,
insofar as blocking ceramide synthesis with Fumonisin B1 reduced cell death. Signalling pathways activated by JWH-015 included JNK
(c-Jun N-terminal kinase) activation and Akt inhibition. In vivo treatment with JWH-015 caused a significant reduction in tumour
growth in mice.
CONCLUSIONS: This study defines the involvement of CB2-mediated signalling in the in vivo and in vitro growth inhibition of prostate
cancer cells and suggests that CB2 agonists have potential therapeutic interest and deserve to be explored in the management of
prostate cancer.
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Prostate cancer has become the most common cancer diagnosed in
men and is one of the major life-threatening diseases in Western
countries (Ukraintseva et al, 2008). Despite recent advances in
its diagnosis and treatment, current therapies are unable to
completely eliminate the androgen-independent prostate cancer
cells that remain after androgen ablation therapy (Bahnson, 2007).
Thus, understanding the mechanisms involved in the control of
tumour growth and the development of chemopreventive agents
are major goals of basic research in oncology.
Cannabinoids, the active components of Cannabis sativa and
their derivatives, exert a wide spectrum of modulatory actions and
pharmacological activities in the brain as well as in the periphery,
and therefore, the therapeutic potential of cannabinoids has gained
much attention during the past few years (Kogan and Mechoulam,
2007). One of the most exciting areas of current research in the
therapeutic potential of cannabinoids is cancer. Recent evidence
suggests that cannabinoids are powerful regulators of cell growth
and differentiation. They have been shown to exert anti-tumoural
effects by decreasing viability, proliferation, adhesion and migra-
tion on various cancer cells, thereby suggesting the potential use of
cannabinoids in the treatment of gliomas, prostate and breast
cancers and malignancies of immune origin (Bifulco et al,
2006; Flygare and Sander, 2008; Sarfaraz et al, 2008; Pisanti et al,
2009). The mechanisms of the anti-tumoural action of
cannabinoids include inhibition of tumour cell proliferation,
induction of cell death, inhibition of cell migration and metastasis,
anti-angiogenic effects and modulation of immune response
(Guzman, 2003; Flygare and Sander, 2008). Various cannabinoids,
especially anandamide and THC, promote apoptosis of astro-
cytoma, glioma, neuroblastoma and pheochromocytoma cells in
culture by a pathway involving cannabinoid receptors (Guzman,
2003; Goncharov et al, 2005; Velasco et al, 2007) and by an
activation of the reticulum stress pathway (Carracedo et al, 2006b;
Salazar et al, 2009a). Moreover, synthetic as well as naturally
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cancer cells, such as thyroid, breast and prostate cancer cells
(revised in Lopez-Rodriguez et al (2005) and Bifulco et al (2008)).
The antitumour effect of cannabinoids has been demonstrated
both in vitro and in vivo, affecting multiple signalling pathways
and biological processes that have been implicated in the
development of the malignant phenotype (Bifulco et al, 2008).
Cannabinoids may target tumour cells by binding to cannabinoid
receptors or by a receptor-independent mechanism. Two canna-
binoid receptors have been identified by molecular cloning to date:
the CB1 receptor, which is highly expressed in the brain and also
present in peripheral tissues, and the CB2 receptor, previously
believed to be expressed primarily in immune and haematopoietic
cells, although more recent studies have also identified CB2
receptors in the brain and in endothelial cells of various origins
(Pertwee, 2006; Mackie, 2008). The CB2 receptor is unrelated to
cannabinoid psychoactivity, and therefore targeting this receptor
is one of the major challenges in cannabinoid therapeutic research
(Ashton et al, 2008). After an interaction with cannabinoid
receptors, cannabinoids trigger several signalling pathways de-
pending on cell type, which may be involved in their anti-
proliferative effects such as p38 MAPK and c-Jun N-terminal
kinase (JNK) activation, increased synthesis of the pro-apoptotic
sphingolipid ceramide and several downstream stress-related
genes expressed in the endoplasmic reticulum (Diaz-Laviada and
Ruiz-Llorente, 2005; Demuth and Molleman, 2006). Ceramide, the
central molecule of sphingolipid metabolism, generally mediates
anti-proliferative responses, such as inhibition of cell growth,
induction of apoptosis and/or modulation of senescence
(Saddoughi et al, 2008). Several therapeutic agents that induce
ceramide-dependent apoptosis in cancerous cells currently exist,
and a number of enzymes involved in ceramide metabolism are
beginning to be recognised as potential targets for cancer
therapy (Savtchouk et al, 2007; Carpinteiro et al, 2008).
Recent research has shown that cannabinoids induce ceramide
accumulation in cancer cells, which is related to the pro-apoptotic
effect of cannabinoids in cancer cells (Guzman et al, 2001;
Velasco et al, 2005).
Prostate cancer cells express both CB1 and CB2 receptors
(Ruiz-Llorente et al, 2003; Sanchez et al, 2003), the expression of
which is significantly higher than that in normal prostate epithelial
cells (Sarfaraz et al, 2005). The impact of cannabinoids on prostate
cancer cell viability is variable and depends on the dose used. Low
doses below the micromolar range induce androgen receptor
expression in the prostate cell line, LNCaP (Sanchez et al, 2003),
whereas doses in the range of micromolar or higher induce
apoptosis (Ruiz et al, 1999; Mimeault et al, 2003) or cell-cycle
arrest (Sarfaraz et al, 2006). The involvement of cannabinoid
receptors in such effects is uncertain as CB1 antagonists blocked
cytotoxic effects at short incubation times (Mimeault et al, 2003;
Sarfaraz et al, 2005), although there was a lack of effect at a longer
duration (Ruiz et al, 1999; Mimeault et al, 2003).
In this study, we analysed the role of CB2 receptor in the
androgen-resistant prostate cell line, PC-3, which represents the
androgen-refractory phase of advanced prostate cancer. We used
the anandamide analogue, R(þ)Methanandamide (MET), for
comparison with previous results, and a potent and selective CB2
receptor agonist, JWH-015 (JWH), as well as CB2 antagonists and
RNA silencing to show the role of CB2 in PC-3 cells.
MATERIALS AND METHODS
Reagents
R(þ)-Metanandamide, JWH-015 [(2-methyl-1-propyl-1H-indol-3-
yl)-1-naphtalenylmethanone] and Fumonisin B1 were purchased
from Sigma (St Louis, MO, USA). SR 144528 (SR2) was kindly
provided by Sanofi Recherche (Montpelier, France). Antibody
anti-CB2 receptor was obtained from Affinity BioReagents (Golden,
CO, USA). We purchased anti-tubulin, anti-phospho Akt at Ser473,
anti-phospho p38, anti-total p38, anti-phospho JNK, anti-total
JNK, anti-phosphor eIF2a, anti-caspase 8 and anti-caspase 9 and
anti-citochrome c antibodies from Cell Signaling Technology
(St Louis, MO, USA). The inhibitor D609 and the enzyme diacyl-
glycerol kinase were supplied by Calbiochem (La Jolla, CA, USA).
Cell cultures
Human prostate epithelial PC-3, DU-145 and LNCaP cells were
purchased from American Type Culture Collection (Rockville, MD,
USA) and were cultivated in RPMI-1640 medium supplemented
with 10% fetal calf serum (FCS), 100Uml
 1 penicillin G,
100mgml
 1 streptomycin and 0.25mgml
 1 amphotericin B
(Invitrogen, Paisley, UK). Low cell passages (between 10 and 20)
were used for this study. Cells were seeded sub-confluently and, 1
day before the experiment, the serum was removed to work with
quiescent cells.
Cell viability assays
Cells were set up 2 10
4cells per well of a 24-well plate and were
cultured in the RPMI 1640 medium supplemented with 10% FCS.
After treatments according to figure legends, cell viability was
assayed by MTT as previously described (Sanchez et al, 2003).
Flow cytometry
Flow cytometry was used to detect apoptotic cells and the
distribution of cell cycle. After being cultivated with medium
alone or medium containing the indicated stimuli, 10
5 cells in a
35-mm culture dish were harvested in 0.1% Nonidet P-40 and
0.5mgml
 1 Rnase for 30min and stained with 0.05mgml
 1 Iodure
Propidium (IP) to indicate the relative DNA content. The sub-G1
peak (DNA content o2N) and cell-cycle distribution were
measured using FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). To analyse apoptosis by Annexin V
staining, the cells were washed twice with PBS and incubated in
0.5ml of binding buffer (10mM HEPES pH 7.4, 150mM NaCl,
2.5mM CaCl2,1m M MgCl2 and 4% BSA), with 4mgml
 1 Annexin
V-FITC for 15min. The cells were then washed in PBS and
re-suspended in the binding buffer with 0.6mgml
 1 IP (Calbiochem).
In all, 20000 cells of each sample were analysed by flow cytometry in
a FACScan (Beckton Dickinson).
Measurement of [
3H]-thymidine incorporation into DNA
Cells were treated with different concentrations of MET or JWH-
015 according to the experiment. DNA synthesis was determined
by pulsing the cells with [
3H]-thymidine (1mCi per well) during the
last 16h of the culture period as previously described (Sanchez
et al, 2003).
siRNA tranfections
Cells were transfected in 1ml OPTIMEN containing 4mg lipofecta-
mine 2000 (Invitrogen Co., Carlsbad, CA, USA), with 100nM
human cannabinoid receptor-2-specific small interfering RNA
(siRNA) duplexes (50-GGCCUCUUCCCAAUUUAAAtt-30, Applied
Biosystems, Foster City, CA, USA) or control scrambled RNA for
12h according to the manufacturer’s protocols (Ambion, Applied
Biosystems). At 24h after transfection, the medium was removed
and replaced with RPMI 1640 with 10% FCS medium. At dedicated
time points after transfection, the cells were used for flow
cytometry assays or western blot.
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Ceramide quantification in cell lipid extracts was performed
according to the method described by Perry et al for ceramide
quantification in cultured cells (Perry et al, 2000). Briefly, cell
pellets were suspended in 0.6ml distilled water, and disrupted at
41C by sonication. Lipids were extracted with chloroform/
methanol, and ceramide content was determined by phosphory-
lation using Escherichia coli diacylglycerol kinase and [
32P]g-ATP
(6000Cimmol
 1; Perkin-Elmer, Barcelona, Spain). Products of this
reaction were purified by TLC using chloroform–acetone–
methanol–acetic acid–water (50:20:15:10:5, by volume) as
the developing solvent. Products of this reaction were quantified
and expressed as a percentage of the value observed earlier
(Sanchez et al, 2007).
Western blot analysis
Cultured cells were lysed into a lysis buffer (50mM Tris-HCl, pH
7.4, 5mM EDTA, 1mM EGTA, 10mM 2-mercaptoethanol) contain-
ing 5mgml
 1 leupeptin, 5mgml
 1 aprotinin and 1mM phenyl-
methylsulfonyl fluoride, and were disrupted by sonication. Protein
concentration was determined using the Bio-Rad protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Western blotting was
carried out as previously described (Sanchez et al, 2006).
In vivo anti-tumour activity
All animal studies were conducted in accordance with the Spanish
institutional regulation for the housing, care and use of experi-
mental animals, have been carried out with ethical committee
approval and met the European Community directives regulating
animal research. Recommendations made by the UKCCCR have
been adhered to carefully. Athymic nude (nu/nu) 6-week-old male
mice were purchased from Harlan Iberica (Barcelona, Spain) and
were housed in a laminar airflow cabinet under pathogen-free
conditions on a 12-h light–dark schedule. Mice were injected
subcutaneously (s.c.) in the right flank with 2 10
6 PC-3 cells in
0.2ml of complete culture medium. Two weeks after transplanta-
tion, tumours had grown to an average volume of 70mm
3. Mice
were then divided into three experimental groups of eight animals
each, which received the following treatments as s.c. injections:
group A, saline (control); group B, 0.15mgkg
 1 body weight (b.w.)
JWH-015; group C, 0.15mgkg
 1 b.w. JWH-015 plus 0.15mgkg
 1
b.w SR2. The injection was repeated every day and treatment was
continued for 14 days. Tumour volumes were monitored every day
using calliper measurements and were calculated using the
following formula: (4p/3) (w/2)
2 (l/2), where w¼width and
l¼length. The b.w. of the animals was recorded daily.
Statistical analysis
Data are presented as mean±s.e. of the number of experiments
indicated. Statistical comparisons among groups were made with
Student’s t-test, and the difference was considered to be
statistically significant when the P-value was o0.05.
RESULTS
The cannabinoids, MET and JWH-015, inhibited cell
growth of prostate cancer cells
We first examined the anti-proliferative effects of the stable
anandamide analogue, MET, and the synthetic CB2 ligand, JWH-
015, on prostate PC-3 cells. The kinetics of MET and JWH-015
treatment showed that cannabinoid-induced cell death was evident
from 12h, although maximal effect was reached at 48–72h
(Figure 1A). Thus, we decided to follow all the studies at 48h.
Cells were incubated in the presence of increasing concentrations
of MET or JWH-015 for 48h, after which cell viability was
evaluated by MTT assay, [
3H]-thymidine incorporation assay or by
flow cytometry. As shown in Figure 1B, both MET and JWH-015
caused a dose-dependent decrease in cell viability, which was
significantly different from control from doses over 5mM. To assess
the suppressive effects of R(þ)-Methanandamide and JWH-015
on the proliferation of PC-3 cells, DNA synthesis was measured
by [
3H]-thymidine incorporation. Results shown in Figure 1C
indicate that both cannabinoids inhibited the proliferation of
PC-3 cells, which was totally blocked from doses over 5mM. The
cell-cycle analysis demonstrated that cannabinoid treatment
resulted in a small, although significant, accumulation of cells in
the sub-G1 phase of the cell cycle (Figure 1D). These results
suggest that the compounds used induced a small percentage of
apoptosis and growth arrest in prostate cells. To investigate
whether the anti-proliferative effect of cannabinoids on prostate
cancer cells was generalised, we used the androgen-refractory
prostate cancer DU-145 cells and the less tumourigenic androgen-
dependent prostate LNCaP cells. Results shown in Figure 2 showed
that both MET and JWH-015 inhibited the growth of the three
cancer prostate lines studied, although the effect was less
pronounced in the androgen-sensitive LNCaP cells. As shown in
Figure 2A, low doses (sub-micromolar) of MET induced a slight
increase in LNCaP cell viability, as previously reported by our
group (Sanchez et al, 2003).
To quantify the percentage of apoptotic cells after drug
treatments, PC-3 cells were stained with Annexin V-FITC/IP.
Results show that the rate of late apoptotic cells (Annexin V-FITC
positive/IP positive, upper right quadrant) in MET- and JWH-015-
treated cells was statistically increased compared with that in
control cells (Figure 3). R(þ)Methanandamide and JWH-15
treatments also induced cell necrosis, as inferred from IP-positive
cells (upper left quadrant). Early apoptotic cells (Annexin V-FITC
positive/IP negative, lower right quadrant) were o5% in all cases.
These findings indicate that both MET and JWH-015 promoted a
low, although significant, percentage of apoptosis in prostate
cancer cells, but other processes such as mitotic catastrophe,
cytotoxicity or necrosis could also collaborate in the observed
growth inhibition.
Involvement of CB2 in the anti-proliferative effect of
cannabinoids
As we have previously shown, prostate PC-3 cells express both CB1
and CB2 cannabinoid receptors (Sanchez et al, 2003). We then
investigated the role of CB1 and CB2 in cannabinoid-induced
prostate cell death. Pharmacological blockage of CB1 with its
antagonist Rimonabant (SR1) did not reduce the effect of MET on
cell cycle or apoptosis (Figure 4A). However, the CB2 antagonist,
SR 144528 (SR2), reduced the number of apoptotic cells and the
number of sub-G1 cells induced by MET treatment (Figure 4A). As
MET is a weak ligand for CB2, we confirmed this result with the
CB2-selective agonist JWH-015. The JWH-015-induced cell death
effect was reverted by SR2, suggesting a role for CB2 in the
apoptotic mechanisms of cannabinoids in PC-3 cells.
To confirm the involvement of CB2, we silenced its expression
with siRNA. PC-3 cells were transfected with CB2-selective siRNA
or control scrambled RNA for 48h, after which the expression of
CB2 was notably reduced as it was corroborated by western
blotting (Figure 5). Under these conditions, apoptosis induced by
10mM JWH-015 was almost totally blocked in cells transfected with
CB2 siRNA when compared with scrambled siRNA-transfected
cells (Figure 5). These results confirm the involvement of CB2
receptor in the pro-apoptotic effect of cannabinoids in prostate
cells. Therefore, we conducted the rest of the experiments with
JWH-015, which is a potent and selective ligand for CB2 and which
exhibits more efficacy than MET for CB2 activation.
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Figure 1 The anti-proliferative effect of the cannabinoids, R(þ)-Methanandamide and JWH-015, on prostate PC-3 cells. (A) Time course of cannabinoid
effect on prostate PC-3 cells viability. PC-3 cells were incubated with 10mM MET or 10mM JWH-015 for different times and cell viability was assayed by MTT.
(B) Cells were incubated in the presence of increasing concentrations of MET or JWH-015 for 48h and cell viability was assayed by MTT. (C) Cells were
incubated in the presence of increasing concentrations of MET or JWH-015 for 48h and cell proliferation was measured by [
3H]-thymidine incorporation.
(D) Cells were incubated in the presence of increasing concentrations of MET or JWH-015 for 48h and cell cycle was assayed by flow cytometry. Data are
the means±s.e. of three different experiments, each performed in triplicate. *Po0.05 and **Po0.01 using Student’s t-test for the comparison between
vehicle-treated and cannabinoid-treated cells.
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induced by CB2 activation
Ceramide is a sphingolipid messenger that has a relevant role in
the regulation of tumour cell fate (Velasco et al, 2005; Carpinteiro
et al, 2008). Recent studies have suggested that apoptosis induced
by cannabinoids can be preceded by ceramide accumulation
(Gomez del Pulgar et al, 2002; Gustafsson et al, 2006). To further
analyse the apoptotic mechanism of JWH-015, we measured
intracellular ceramide concentration in PC-3 cells. As shown in
Figure 6A, incubation with JWH-015 for 48h led to a dose-
dependent increase in intracellular ceramide accumulation. This
effect was prevented by the CB2 antagonist SR2, which indicates
that ceramide accumulation was mediated by the activation of CB2
(Figure 6B). Ceramide is formed in cellular membranes by de novo
synthesis through a pathway involving the ceramide synthase or by
hydrolysis of sphingomyelin catalysed by acid, neutral and alkaline
sphingomyelinases. To gain insight into the origin of JWH-015-
induced ceramide increase, cells were incubated in the presence of
the ceramide synthase inhibitor, Fumonisin B1, or the sphingo-
myelinase inhibitor, D609. As shown in Figure 6B, treatment of
cells with 10mM Fumonisin B1, but not with D609, prevented the
increase in ceramide concentration, a fact that suggests that
ceramide came from de novo biosynthesis.
Moreover, treatment with Fumonisin B1 prevented the inhibi-
tion of cell growth induced by JWH-015 (Figure 6C), indicating
that ceramide biosynthesis was involved in the action of the
cannabinoid.
Signal mechanisms involved in JWH-015-induced prostate
PC-3 cell death
To further explore the signalling pathways in which the CB2
agonist exerted its effect in prostate PC-3 cells, we studied stress-
related MAP kinase cascades activation by western blot. PC-3 cells
were treated for different times with 10mM JWH-015 and then
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incubated with different doses of JWH-015 for 48h and cell viability was
assayed by MTT. Data are means±s.e. of two different experiments, each
performed in triplicate. *Po0.05 and **Po0.01 using Student’s t-test for
the comparison between vehicle-treated and cannabinoid-treated cells.
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Figure 3 Evaluation of apoptosis by Annexin V-FITC/IP staining, followed by flow cytometry analysis. Representative plots of Annexin V-FITC/IP staining
of PC-3 cells cultured in the presence of increasing concentrations of MET or JWH-015 are shown. Data showing the percentage of late apoptotic cells
(upper right quadrant) are the mean±s.e. of three different experiments, each performed in duplicate. *Po0.05 and **Po0.01 using Student’s t-test for the
comparison between vehicle-treated and cannabinoid-treated cells.
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Figure 4 Inhibition of cannabinoid-induced cell death by the CB2 antagonist, SR 144528 (SR2). PC-3 cells were incubated with 10mM MET or 10mM JWH-
015 for 48h in the presence or absence of 0.5mM Rimonabant (SR1) or 2mM SR2. Apoptosis was assayed by Annexin V-FITC/IP staining (panels A and C)
and cell cycle was measured by IP staining (panels B and D). Representative plots are shown in the figure and data are the mean±s.e. of three different
experiments, each performed in duplicate. *Po0.05 and **Po0.01 using Student’s t-test for the comparison between vehicle-treated and cannabinoid-
treated cells, and
#Po0.05 and
##Po0.01 for the comparison between cannabinoid-treated and antagonist-treated cells.
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sphosphorylated forms of JNK and p-38 kinases, indicative for
activated kinases, were detected by western blot. Results in
Figure 7A show that JWH-015 activates the stress-signal-related
kinase JNK as phosphorylated JNK is increased at 30min and 1h
of treatment.
Eukaryotic cells respond to stress in their endoplasmic
reticulum by phosphorylating the a-subunit of translation initia-
tion factor 2 (eIF2a). This adaptation inhibits general protein
synthesis while promoting translation and expression transcrip-
tional regulators that induce gene expression important for cellular
remediation and apoptosis. It has recently been described
that cannabinoids promote endoplasmic reticulum stress and
autophagy-mediated cell death in glioma cells through the Akt/
mammalian target of rapamycin (mTOR) pathway inhibition and
eIF2a activation (Salazar et al, 2009b). To investigate whether
JWH-015 regulated this pathway in prostate cells, we treated the
cells with the CB2 agonist and measured the phosphorylation of
Akt in Ser473, which is negatively involved in the autophagy
pathway (Todde et al, 2009). PC-3 treatment with 10mM JWH-015
resulted in a long-term AKT phosphorylation decrease that was
evident from 6h of treatment (Figure 7A). This was in
concordance with the increase in phosphorylated eIF2a
(Figure 7A), suggesting that endoplasmic reticulum stress signals
were activated by JWH-015 in prostate cells. We further
investigated whether JWH-015 induced caspase activation, which
can be detected after the decrease in the pro-caspase form and the
increase in the proteolytic active form by western blot (Hoffmann
et al, 2009). Results in Figure 7 show that JWH-015 induced
activation of caspase 9, which has been described as an initiator
caspase essential in the intrinsic or mitochondrially gated pathway
of apoptosis (Johnson and Jarvis, 2004; Denault and Salvesen,
2008). To further confirm the activation of the intrinsic apoptotic
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Figure 5 CB2 is involved in the anti-proliferative effect of JWH-015 in PC-3 cells. Cells were transfected with CB2-specific small interfering RNA (siRNA)
or with control scrambled RNA for 48h and then treated with 10mM JWH-015 for an additional 48h. Cell apoptosis or cell cycle was assayed by flow
cytometry. A representative plot is shown. Data are the mean±s.e. of two different experiments performed in duplicate. *Po0.05 using Student’s t-test for
the comparison between control and JWH-015-treated cells. Upper panel, western blot for CB2 in control (scrambled) and CB2 siRNA-transfected cells.
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spathway, we determined the cytosolic levels of cytochrome c,
which is released into the cytosol when the cell receives an
apoptotic stimulus to trigger programmed death through caspase 9
activation (Ow et al, 2008).
JWH-015 caused regression of prostate cancer xenografts
in nude mice
The above observations of the anti-proliferative effects of JWH-015
were examined in a xenograft model of prostate cancer. Xenograft
human prostate tumours were established in nu/nu mice by a s.c.
injection. Tumour-bearing animals (B70mm
2) were treated daily
with vehicle, 1.5mgml
 1 JWH-015 or 1.5mgml
 1 JWH-015 plus
1.5mgkg
 1 SR2. Animals were treated for 15 days and tumour
volume was calculated every day. At the end of the experiment,
tumours were dissected and weighed. As shown in Figure 8, JWH-
015-treated animals had a rapid and dramatic reduction in tumour
growth, whereas uncontrolled growth was observed in the control
group. The final tumour volume as well as the final tumour weight
was significantly lower in the JWH-015-treated group compared
with that in the control group (Table 1). Treatment with JWH-015
plus SR2 resulted in a similar growth compared with that in the
control group, suggesting that the in vivo effect of JWH-015 is also
mediated through CB2 activation (Figure 8 and Table 1).
DISCUSSION
Deregulation of cell survival pathways and resistance to apoptosis
are widely accepted to be fundamental aspects of tumourigenesis,
as evasion of apoptosis may contribute to carcinogenesis, tumour
progression and also to treatment resistance. Most current
anticancer therapies act by activating cell death pathways in
cancer. A number of studies have recently shed light on the role of
cannabinoid family members as anticancer agents, allowing the
potential development of anti-neoplasic-efficient treatments.
In this study, we demonstrated that the stable anandamide
analogue, MET, as well as JWH-015, a cannabinoid receptor type 2-
selective agonist, inhibited the proliferation of human prostate
cancer PC-3, DU-145 and LNCaP cells. The fact that the anti-
proliferative effect of cannabinoids was less pronounced in LNCaP
cells is in agreement with previous results showing a higher
expression of CB2 in PC-3 and DU-145 cells than in LNCaP cells
(Sarfaraz et al, 2005) and points to a CB2-mediated effect. We then
demonstrated that CB2 was involved in cannabinoid-induced PC-3
cell death, in that blocking its activation with a specific antagonist
(SR2) almost totally prevented cell death after incubation of cells
with MET and JWH-015. The role of CB2 receptors in the anti-
proliferative effect of cannabinoids is further supported by results
obtained by knocking down CB2 mRNA with the use of selective
siRNA. There is now a large body of data indicating that the
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Figure 6 Involvement of ceramide synthesis in JWH-015-induced cell growth inhibition. (A) PC-3 cells were incubated in the presence of increasing
concentrations of JWH-015 for 48h and intracellular ceramide was measured by the DAG kinase method as indicated in the Methods section. (B) PC-3 cells
were incubated with 10mM JWH-015in the presence or absence of 2mM SR2, 50mM Fumonisin B1 (Fumo) or 5mM D609 for 48h and intracellular ceramide
was assayed as above. (C) Cell cycle of PC-3 cells incubated with 10mM JWH-015±50mM Fumo for 48h. Data are the mean±s.e. of three different
experiments performed in duplicate. *Po0.05 and **Po0.01 using Student’s t-test for the comparison between vehicle-treated and JWH-015-treated cells,
and
#Po0.01 for the comparison between JWH-015-treated and inhibitor-treated cells.
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scannabinoid receptor type 2 is linked to various responses related
to the proliferation, differentiation and survival of many cell types
(Fernandez-Ruiz et al, 2007; Svizenska et al, 2008). Our observa-
tions are consistent with previous reports showing that CB2
receptor stimulation is involved in cannabinoid anti-tumour
activity in vitro and in mice inoculated with tumour xenografts
in vivo (Caffarel et al, 2006; Carracedo et al, 2006a; Fernandez-Ruiz
et al, 2007). As previously proposed, this receptor may function as
a signal favouring a non-differentiated, proliferate state of cells
(Fernandez-Ruiz et al, 2007). In keeping with this notion,
increased levels of CB2 have been shown in prostate cancer cells
compared with normal prostate (Sarfaraz et al, 2008), and a
correlation between CB2 expression and the histological grade of
breast tumours has also been observed (Caffarel et al, 2006).
Activation of the CB2 receptor induces apoptosis and reduces
tumour growth of glioma (Sanchez et al, 2001; Blazquez et al,
2008), pancreatic carcinoma (Carracedo et al, 2006a) or breast
cancer (Caffarel et al, 2006). Moreover, recent research shows that
the anti-tumour action of cannabinoid receptor agonists in colon
cancer cells may be exerted through the CB2 receptor more
efficiently that through the CB1 receptor (Cianchi et al, 2008),
which is consistent with our results in prostate cells.
Our data show that CB2 receptor activation by JWH-015 in
prostate PC-3 cells induces de novo synthesis of ceramide, which
mediates the apoptotic effect of JWH-015 in that the addition of
the ceramide synthase inhibitor Fumonisin B1 prevented the
induction of apoptosis. Ceramide is a second messenger that has
been shown to act as a pro-apoptotic lipid mediator of
cannabinoid action (Guzman et al, 2001). It has been previously
described that, although CB1 receptor activation induces acute
ceramide increase through sphingomyelin hydrolysis (Sanchez
et al, 1998), sustained ceramide accumulation through enhanced
de novo synthesis seems to exert a major effect in CB2-induced
apoptosis (Gomez del Pulgar et al, 2002; Herrera et al, 2006;
Carracedo et al, 2006a; Cianchi et al, 2008), which is in good
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Figure 7 Signalling mechanisms activated by JWH-015 in prostate PC-3
cells. Cells were incubated with 10mM JWH-015 for different times. (A)
Phosphorylation levels of p38, JNK, Akt and eIF2a were measured by
western blot. (B) Levels of pro-caspase 8, pro-caspase 9 and cytochrome c
in the cell cytosol were detected by western blot. Figure shows a
representative image of the other three experiments. Tubulin levels are
shown as loading control.
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Figure 8 In vivo anti-tumoural properties of JWH-015. Athymic nude
mice were injected s.c. in the right flank with PC-3 cells and 4 weeks
later (day 0) were treated for 15 days with vehicle (control), 1.5mgkg
 1
JWH-015 or 1.5mgkg
 1 JWH-015 plus 1.5mgkg
 1 SR2. Treatments were
carried out by injections in the peritumoural area every day. Tumour
volumes were measured daily. (A) The dorsal side of representative
mice and dissected tumours after treatment. (B) Tumour growth curve
after administration of vehicle (diamonds), JWH-015 (squares) or JWH-
015þSR2 (triangles). Results represent the mean±s.e. of eight mice in
each group. *Po0.01 vs control and
#Po0.01 vs JWH-015, compared by
Student’s t-test.
Table 1 Effect of JWH-015 on PC-3 xenograft tumour growth
Initial tumour volume (mm
3) Final tumour volume (mm
3) % tumour growth Tumour weight (lg)
Control 77.61±25.82 449.02±72.41 715.08±121.90 221.28±28.08
JWH-015 77.36±13.66 350.09±66.11 396.48±50.10 148.85±29.15
JWH-015+SR2 71.33±14.00 415.75±81.12 644.32±135.45 236.16±47.00
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sagreement with our data. Many anticancer drugs also induce death
by stimulating the generation of ceramide (Claria, 2006; Lin et al,
2006). Ceramide mediates the apoptosis of radiation therapy
(Moeller et al, 2009), and attenuation of ceramide levels confers
resistance to radiation in prostate cancer cells (Mahdy et al, 2009).
Ceramide has been shown to activate a number of enzymes
involved in stress signalling cascades, including stress-activated
protein kinases such as the Jun kinases JNKs, which are involved
in ceramide-mediated apoptosis induction (Ruvolo, 2003). Our
data demonstrate that JWH-015 activates JNK in prostate cells,
which is in agreement with previous results showing a CB2-
dependent activation of JNK in microglial cells (Correa et al, 2009)
and in lung epithelial cells (Sarafian et al, 2008). This study also
demonstrated that JWH-015 inhibits the Akt–mTOR pathway and
activates eIF2a, which are involved in autophagy regulation and
endoplasmic reticulum stress response, suggesting that these
pathways are involved in JWH-015-induced prostate cell death.
The release of pro-apoptotic factors such as cytochrome c from the
mitochondria leads to the formation of a multimeric complex
known as apoptosome and initiates caspase activation cascades.
The fact that JWH-015 induced cytochrome c release into cytosol
and activated caspase 9 in prostate PC-3 cells confirms the
involvement of apoptosis and points to an activation of the
intrinsic apoptotic pathway. An improved understanding of the
downstream mechanisms of prostate cell death induced by
cannabinoids in prostate cells would offer new opportunities for
the development of a combination therapy in the treatment of
prostate cancer. Overall, our data show a role for the cannabinoid
receptor CB2 in the anti-tumour effect of cannabinoids on prostate
cells in vitro and in vivo. There is considerable interest in the
application of selective CB2 receptor agonists, which are devoid of
typical marijuana-like psychoactive properties of CB1 agonists, for
future cannabinoid-based anticancer therapies. Therefore, our
findings point to the potential application of cannabinoid receptor
type 2 ligands as anti-tumour agents in prostate cancer.
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